Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "Check point inhibitors" OR "Renal cell carcinoma" OR "Bladder cancer" OR "Nivolumab" OR "Pembrolizuamb":

Search results

Items: 1 to 20 of 78334

1.

Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.

Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T.

J Gastroenterol Hepatol. 2019 Nov 21. doi: 10.1111/jgh.14889. [Epub ahead of print] German.

PMID:
31752049
2.

New immunotherapy in the treatment of advanced renal cancer.

Muto A, Gridelli C.

Expert Opin Emerg Drugs. 2019 Nov 21. doi: 10.1080/14728214.2019.1696308. [Epub ahead of print]

PMID:
31751164
3.

Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.

Agrawal S, Haas NB, Bagheri M, Lane BR, Coleman J, Hammers H, Bratslavsky G, Chauhan C, Kim L, Krishnasamy VP, Marko J, Maher VE, Ibrahim A, Cross F Jr, Liu K, Beaver JA, Pazdur R, Blumenthal GM, Singh H, Plimack ER, Choueiri TK, Uzzo R, Apolo AB.

JAMA Oncol. 2019 Nov 21. doi: 10.1001/jamaoncol.2019.4117. [Epub ahead of print]

PMID:
31750870
4.

Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab vs. ipilimumab plus nivolumab in US academic centers.

Joseph RW, Shillington AC, Lee TA, Macahilig CP, Diede SJ, Dave V, Harshaw Q, Scherrer E, Liu FX.

J Med Econ. 2019 Nov 21:1. doi: 10.1080/13696998.2019.1696349. [Epub ahead of print]

PMID:
31750751
5.

Characteristics of clear cell renal cell carcinoma metastases to the thyroid gland: A systematic review.

Khaddour K, Marernych N, Ward WL, Liu J, Pappa T.

World J Clin Cases. 2019 Nov 6;7(21):3474-3485. doi: 10.12998/wjcc.v7.i21.3474.

PMID:
31750330
6.

Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases.

Vaishampayan U, George J, Vigneau F.

J Kidney Cancer VHL. 2019 Oct 28;6(1):13-25. doi: 10.15586/jkcvhl.2019.121. eCollection 2019.

PMID:
31750074
7.

Abscopal effect of high-dose-rate brachytherapy on pelvic bone metastases from renal cell carcinoma: a case report.

Suzuki G, Masui K, Yamazaki H, Takenaka T, Asai S, Taniguchi H, Nakamura T, Ukimura O, Yamada K.

J Contemp Brachytherapy. 2019 Oct;11(5):458-461. doi: 10.5114/jcb.2019.89365. Epub 2019 Oct 30.

PMID:
31749855
8.

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis.

Xu H, Tan P, Ai J, Zhang S, Zheng X, Liao X, Yang L, Wei Q.

Front Pharmacol. 2019 Nov 4;10:1300. doi: 10.3389/fphar.2019.01300. eCollection 2019.

PMID:
31749704
9.

Detection and segmentation of multi-class artifacts in endoscopy.

Zhang YY, Xie D.

J Zhejiang Univ Sci B. 2019 Dec.;20(12):1014-1020. doi: 10.1631/jzus.B1900340.

PMID:
31749348
10.

Cancer-associated fibroblasts-derived exosomes-mediated transfer of LINC00355 regulates bladder cancer cell proliferation and invasion.

Yan L, Wang P, Fang W, Liang C.

Cell Biochem Funct. 2019 Nov 21. doi: 10.1002/cbf.3462. [Epub ahead of print]

PMID:
31749189
11.

Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis.

Tully KH, Krimphove Md MJ, Huynh MJ, Marchese M, Kibel AS, Noldus J, Kluth LA, McGregor B, Chang SL, Trinh QD, Mossanen M.

World J Urol. 2019 Nov 20. doi: 10.1007/s00345-019-03003-2. [Epub ahead of print]

PMID:
31748954
12.

Prognostic Significance of Cyclin D1 Expression in Renal Cell Carcinoma: a Systematic Review and Meta-analysis.

Li Z, Liu J, Zhang X, Fang L, Zhang C, Zhang Z, Yan L, Tang Y, Fan Y.

Pathol Oncol Res. 2019 Nov 20. doi: 10.1007/s12253-019-00776-0. [Epub ahead of print] Review.

PMID:
31748879
13.

Examining the upper urinary tract in patients with hematuria-time to revise the CT urography protocol?

Rud E, Galtung KF, Lauritzen PM, Baco E, Flatabø T, Sandbæk G.

Eur Radiol. 2019 Nov 20. doi: 10.1007/s00330-019-06521-0. [Epub ahead of print]

PMID:
31748856
14.

Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.

Higuchi K, Sakamoto S, Ando K, Maimaiti M, Takeshita N, Okunushi K, Reien Y, Imamura Y, Sazuka T, Nakamura K, Matsushima J, Furihata T, Ikehara Y, Ichikawa T, Anzai N.

Sci Rep. 2019 Nov 20;9(1):16776. doi: 10.1038/s41598-019-53397-7.

PMID:
31748583
15.

De novo cancer incidence after kidney and liver transplantation: Results from a nationwide population based data.

Park B, Yoon J, Choi D, Kim HJ, Jung YK, Kwon OJ, Lee KG.

Sci Rep. 2019 Nov 20;9(1):17202. doi: 10.1038/s41598-019-53163-9.

PMID:
31748582
16.

You're the Flight Surgeon: Renal Cell Carcinoma.

[No authors listed]

Aerosp Med Hum Perform. 2019 Dec 1;90(12):1064-1068. doi: 10.3357/AMHP.5452.2019.

PMID:
31748005
17.

Upregulation of ERp57 promotes clear cell renal cell carcinoma progression by initiating a STAT3/ILF3 feedback loop.

Liu Y, Wang JX, Nie ZY, Wen Y, Jia XJ, Zhang LN, Duan HJ, Shi YH.

J Exp Clin Cancer Res. 2019 Oct 30;38(1):439. doi: 10.1186/s13046-019-1453-z.

PMID:
31747963
18.

Development and validation of a metastasis-associated prognostic signature based on single-cell RNA-seq in clear cell renal cell carcinoma.

Zhang C, He H, Hu X, Liu A, Huang D, Xu Y, Chen L, Xu D.

Aging (Albany NY). 2019 Nov 20;11. doi: 10.18632/aging.102434. [Epub ahead of print]

19.

Prescribing trend of pioglitazone after safety warning release in Korea.

Jeong HE, Cho SI, Oh IS, Baek YH, Shin JY.

Am J Manag Care. 2019 Nov 1;25(11):e342-e348.

20.

Review article: new therapeutic interventions for advanced hepatocellular carcinoma.

Bangaru S, Marrero JA, Singal AG.

Aliment Pharmacol Ther. 2019 Nov 20. doi: 10.1111/apt.15573. [Epub ahead of print] Review.

PMID:
31747082

Supplemental Content

Loading ...
Support Center